Retatrutide Dosage: Studied Doses Only, Not Approved

There is no approved retatrutide dosage. Retatrutide is an investigational medicine from Eli Lilly that has not been approved by the FDA for any use, so no doctor can prescribe it as a normal medicine and no pharmacy can lawfully supply it. This page explains, in general terms only, what doses researchers studied in trials and why those numbers are not guidance for anyone to use.

The most important fact first

Retatrutide is investigational and not FDA approved. That single fact answers most dosage questions. Approved medicines have a prescribing label that sets a starting dose, a schedule for increases, a maintenance dose and a maximum dose, all tested for safety and reviewed by regulators. Retatrutide has no such label. Without a label, there is no official dose to follow, no approved dosing schedule to copy, and no legal product whose strength and purity have been checked in the way approved medicines are checked.

Interest in retatrutide is understandable. It has been widely reported as a next generation weight loss medicine, and early trial coverage used large headline numbers. That coverage can make it sound as if the medicine is already available with a standard dose. It is not. At the time of writing, the manufacturer had reported late stage trial results and had said it planned a future regulatory submission, but a submission is not an approval, and approval would still require a full FDA review. Until that process finishes, retatrutide belongs in clinical trials, not in routine care.

What doses were studied in trials, in general terms

In published research, retatrutide was given as a once weekly injection under the skin, which matches the weekly pattern used by several approved GLP-1 medicines. Trial participants started on a low dose and, in the research protocols, the dose was raised gradually over time toward a higher maintenance level. Researchers studied a range of weekly doses, from low single digit milligram amounts up to a highest studied dose in the low double digits of milligrams. Different trials used different target doses so that researchers could compare how both benefits and side effects changed as the dose rose.

That description is deliberately general. The exact steps in a trial protocol were designed for a screened group of volunteers who were monitored closely, had regular checks, and could stop with medical support. A trial protocol is a research tool. It is not a prescription, it is not a recommendation, and it should never be presented as a schedule for a reader to follow on their own. This page therefore does not publish a week by week retatrutide schedule, because doing so would imply a level of safety and approval that does not exist.

Why trial doses cannot be used as personal guidance

Several safeguards exist in a trial that do not exist outside one. Participants are screened for conditions that could make the medicine unsuitable. Their dose is supplied from a single controlled source, so the identity and strength are known. They are followed for side effects, blood tests and other measures, and the study team can pause or stop treatment. A person who buys a vial online has none of those safeguards. They cannot know for certain what is in the vial, how strong it is, whether it was stored correctly, or whether it contains something else entirely.

Dose also interacts with a persons other conditions and medicines. Approved labels carry warnings, contraindications and instructions for missed doses and for people with kidney, stomach or thyroid concerns. Retatrutide has no approved label to provide that framework. Copying a number from a trial report or a social media post removes all of that context and leaves only the riskiest part, the dose itself, without any of the monitoring that made the trial setting safer.

Warning against buying retatrutide

Products sold online as retatrutide, often labeled as research chemicals or research peptides and marked not for human use, are not approved medicines. The FDA has stated that retatrutide cannot be used in compounding under federal law. That means a compounding pharmacy cannot lawfully turn it into a prescription product for a patient in the way that was sometimes done with other ingredients during past shortages. A research chemical label does not create a legal or medical exception. It is a warning that the product was not made or checked as a human medicine.

The risks are practical as well as legal. Unapproved products may be fake, impure, too weak, too strong or contaminated, and there is no reliable way for a buyer to tell by looking at a vial or a website. Sellers may use trial photographs, copied branding or false claims of pharmacy sourcing. If a site offers to sell retatrutide for personal use, offers a dosage chart for buyers, or suggests a starting dose, those are strong signs to stay away. The same caution applies to med spas or clinics offering it as a treatment, because there is no lawful retail or clinic channel for this medicine while it remains unapproved.

How retatrutide dosing compares with approved medicines

Approved weekly medicines such as Wegovy and Zepbound have published labels with a slow increase over many weeks toward a maintenance dose. Their labels, reproduced on the dosage chart guides on this site, show why titration is slow: stomach related side effects are most likely when the dose rises, and a gradual increase gives the body time to adjust. Retatrutide research used a similarly gradual idea in principle, but similarity in principle is not the same as an approved schedule. Readers who need treatment now should discuss the approved options, with their known labels and monitoring, with their own doctor rather than waiting for or seeking out an unapproved one.

If and when regulators approve retatrutide in the future, the approved label will be the only reliable source for its dosage. The label could differ from what any single trial studied, because regulators review the full body of evidence and may choose a narrower dose range or add specific warnings. Any page that claims to know the future approved dose before that label exists is guessing.

What to do if you have already been offered retatrutide

If a seller, clinic or social media account has offered you retatrutide, do not start it based on that offer. If you have already used a product sold under that name, telling your own doctor honestly is the safest step, even if it feels awkward, because they need a complete picture to advise you and to watch for problems. Keep any packaging or order details if you can, as that information can help a clinician or a regulator understand what was supplied. For current treatment, ask about approved medicines and about whether a legitimate clinical trial is recruiting in your area, since a trial is the lawful way investigational medicines are provided, with screening and monitoring built in.

Frequently asked questions

Back to all GLPKit guides